Publication | Open Access

Activity and safety of ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial

MedicinePathologyImmune Checkpoint InhibitorCancer TreatmentOncologyRadiation OncologyLung CancerMolecular Oncology